鲁索替尼治疗并发耶氏肺孢子菌肺炎
Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.
作者信息
Lee Samantha C, Feenstra John, Georghiou Paul R
机构信息
School of Medicine, University of Queensland, St Lucia, Queensland, Australia.
School of Medicine, University of Queensland, St Lucia, Queensland, Australia Department of Thoracic Medicine, The Wesley Hospital, Auchenflower, Queensland, Australia.
出版信息
BMJ Case Rep. 2014 Jun 2;2014:bcr2014204950. doi: 10.1136/bcr-2014-204950.
Abstract
Ruxolitinib is a novel inhibitor of the Janus kinase (JAK) pathway that has become available for the treatment of myelofibrosis. There are increasing reports of opportunistic infections associated with ruxolitinib therapy. We present a case of Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. Clinicians should consider the use of pneumocystis prophylaxis when using ruxolitinib.
摘要
芦可替尼是一种新型的Janus激酶（JAK）通路抑制剂，已被用于治疗骨髓纤维化。越来越多的报告指出芦可替尼治疗会引发机会性感染。我们报告了1例因芦可替尼治疗而并发耶氏肺孢子菌肺炎的病例。临床医生在使用芦可替尼时应考虑预防性使用抗肺孢子菌药物。
相似文献
1
Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.
BMJ Case Rep. 2014 Jun 2;2014:bcr2014204950. doi: 10.1136/bcr-2014-204950.
2
[Ruxolitinib prescription in myelofibrosis].
Bull Cancer. 2013 Sep;100(9):897-902. doi: 10.1684/bdc.2013.1792.
3
Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib.
Dermatol Online J. 2014 Oct 15;20(10):13030/qt2jg3q02x.
4
JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.
Leukemia. 2014 Aug;28(8):1736-8. doi: 10.1038/leu.2014.86. Epub 2014 Feb 26.
5
Long-term outcome of treatment with ruxolitinib in myelofibrosis.
N Engl J Med. 2011 Oct 13;365(15):1455-7. doi: 10.1056/NEJMc1109555.
6
Hepatitis B virus reactivation associated with ruxolitinib.
Ann Hematol. 2014 Jun;93(6):1075-6. doi: 10.1007/s00277-013-1936-5. Epub 2013 Oct 31.
7
Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Intern Med. 2020 Jan 15;59(2):229-233. doi: 10.2169/internalmedicine.3528-19. Epub 2019 Sep 18.
8
Cavitary lung lesions caused by in a patient with myelofibrosis on ruxolitinib.
BMJ Case Rep. 2024 Aug 30;17(8):e258468. doi: 10.1136/bcr-2023-258468.
9
Ruxolitinib for myelofibrosis--an update of its clinical effects.
Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):638-45. doi: 10.1016/j.clml.2013.09.006. Epub 2013 Oct 2.
10
Ruxolitinib: the first agent approved for myelofibrosis.
Clin Adv Hematol Oncol. 2012 Feb;10(2):111-3.
引用本文的文献
1
An Observational Analysis of a Large Cohort of Pneumonia.
Open Forum Infect Dis. 2025 Jul 3;12(7):ofaf390. doi: 10.1093/ofid/ofaf390. eCollection 2025 Jul.
2
Cavitary lung lesions caused by in a patient with myelofibrosis on ruxolitinib.
BMJ Case Rep. 2024 Aug 30;17(8):e258468. doi: 10.1136/bcr-2023-258468.
3
Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.
J Fungi (Basel). 2024 Mar 31;10(4):264. doi: 10.3390/jof10040264.
4
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.
J Fungi (Basel). 2021 Dec 10;7(12):1058. doi: 10.3390/jof7121058.
5
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.
Cancers (Basel). 2021 Sep 23;13(19):4750. doi: 10.3390/cancers13194750.
6
Ruxolitinib Alleviates Uveitis Caused by Endotoxin.
Microorganisms. 2021 Jul 11;9(7):1481. doi: 10.3390/microorganisms9071481.
7
Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations.
Cancers (Basel). 2020 Oct 26;12(11):3132. doi: 10.3390/cancers12113132.
8
Hyperlactatemia in diabetic ketoacidosis is common and can be prolonged: lactate time-series from 25 intensive care admissions.
J Clin Monit Comput. 2021 Aug;35(4):757-764. doi: 10.1007/s10877-020-00532-9. Epub 2020 May 20.
9
The CoV-2 outbreak: how hematologists could help to fight Covid-19.
Pharmacol Res. 2020 Jul;157:104866. doi: 10.1016/j.phrs.2020.104866. Epub 2020 May 6.
10
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.
Infect Drug Resist. 2020 Apr 8;13:1017-1021. doi: 10.2147/IDR.S249030. eCollection 2020.
本文引用的文献
1
Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment.
J Am Acad Dermatol. 2014 Mar;70(3):e59-60. doi: 10.1016/j.jaad.2013.09.035.
2
Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.
Leukemia. 2014 Feb;28(2):449-51. doi: 10.1038/leu.2013.296. Epub 2013 Oct 22.
3
Bilateral toxoplasmosis retinitis associated with ruxolitinib.
N Engl J Med. 2013 Aug 15;369(7):681-3. doi: 10.1056/NEJMc1302895.
4
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.
Leukemia. 2014 Jan;28(1):225-7. doi: 10.1038/leu.2013.235. Epub 2013 Aug 9.
5
Progressive multifocal leukoencephalopathy associated with ruxolitinib.
N Engl J Med. 2013 Jul 11;369(2):197-8. doi: 10.1056/NEJMc1302135.
6
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
Blood. 2013 Aug 15;122(7):1192-202. doi: 10.1182/blood-2013-03-484642. Epub 2013 Jun 14.
7
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Chest. 2013 May;143(5):1478-1479. doi: 10.1378/chest.12-1604.
8
Ruxolitinib: a new treatment option for myelofibrosis.
Pharmacotherapy. 2013 Jan;33(1):84-92. doi: 10.1002/phar.1165.
9
Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.
BMC Res Notes. 2012 Oct 5;5:552. doi: 10.1186/1756-0500-5-552.
Zotero 插件